Population Pharmacokinetic Model of Amikacin and Vancomycin in Critically Ill Patients - Trial NCT06261164
Access comprehensive clinical trial information for NCT06261164 through Pure Global AI's free database. This phase not specified trial is sponsored by University Clinical Centre of Republic of Srpska and is currently Recruiting. The study focuses on Sepsis. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University Clinical Centre of Republic of Srpska
Timeline & Enrollment
N/A
Jan 31, 2024
Jan 31, 2025
Primary Outcome
Development of population pharmacokinetic model
Summary
The object of the scientific research is the characterization of the pharmacokinetic profile
 and the investigation of factors of pharmacokinetic variability of amikacin and vacnomycin in
 critically ill patients with a diagnosis of sepsis-like condition (SIRS), hospital-acquired
 sepsis and/or septic shock and who are on extracorporeal therapy with Cytosorb® and Oxiris®
 adsorbents.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06261164
Device Trial